000			03538nam a22003975i 4500
001			286720
003			MX-SnUAN
005			20160429154513.0
007			cr nn 008mamaa
008			150903s2012 xxu| o |||| 0|eng d
020			_a9781461406136 _99781461406136
024	7		_a10.1007/9781461406136 _2doi
035			_avtls000340352
039		9	_a201509030347 _bVLOAD _c201404300414 _dVLOAD _y201402061023 _zstaff
040			_aMX-SnUAN _bspa _cMX-SnUAN _erda
050		4	_aRC261-271
100	1		_aTerabe, Masaki. _eeditor. _9315527
245	1	0	_aNatural Killer T cells : _bBalancing the Regulation of Tumor Immunity / _cedited by Masaki Terabe, Jay A. Berzofsky.
250			_a1.
264		1	_aNew York, NY : _bSpringer New York, _c2012.
300			_axii, 208 páginas _brecurso en línea.
336			_atexto _btxt _2rdacontent
337			_acomputadora _bc _2rdamedia
338			_arecurso en línea _bcr _2rdacarrier
347			_aarchivo de texto _bPDF _2rda
490	0		_aCancer Drug Discovery and Development
500			_aSpringer eBooks
505	0		_aPreface.-  Introduction: Mechanisms of NKT cell-mediated adjuvant activity and function of iPS-derived NKT cells -- Structure and Recognition of Antigens for Invariant NKT Cells -- Invariant NKT cell-based vaccine strategies -- Immune regulation of tumor immunity by NKT cells -- The Regulation of CD1d+ and CD1d- tumors by NKT Cells -- DC-based immunotherapy targeting NKT cells -- Therapeutic Approaches Utilising NKT Cells -- NKT Cells of Cancer Patients & How Models can Inform Therapeutic Plans -- Understanding the role of Natural Killer T (NKT) cells in hematologic malignancies: progress and challenges -- Clinical trials with ?-galactosylceramide (KRN7000) in advanced cancer -- Clinical trials of invariant Natural Killer T cell-based immunotherapy for cancer -- Index.  .
520			_aNatural killer T (NKT) cells are CD1d-restricted T cells that respond to lipid, not protein, antigens presented by CD1d, which is a non-classical MHC class I-like molecule.  This relatively small but pivotal T cell population bridges the gap between innate and adaptive immunity by rapidly produce large amounts of many kinds of cytokines and by providing the T cell arm of the adaptive immune system a mechanism to detect lipid antigens. NKT cells also have both regulatory and effector functions and have been shown to play critical roles in the regulation of immune responses in many disease settings including cancer. Stimulating the protective functions of NKT cells while inhibiting the negative regulatory activity shows promise for the therapy of cancer and several approaches are in clinical trials.               This book reviews what we have learned about NKT cells during last two decades through functional studies in the context of tumor immunology, including clinical trials of NKT cell targeted therapy.  This knowledge should also be informative to understand the role of this underappreciated T cell population in many other fields outside of tumor immunology.
590			_aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700	1		_aBerzofsky, Jay A. _eeditor. _9315528
710	2		_aSpringerLink (Servicio en línea) _9299170
776	0	8	_iEdición impresa: _z9781461406129
856	4	0	_uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-1-4614-0613-6 _zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942			_c14
999			_c286720 _d286720